» Articles » PMID: 21856269

Secondary, Somatic Mutations Might Promote Cyst Formation in Patients with Autosomal Dominant Polycystic Liver Disease

Overview
Specialty Gastroenterology
Date 2011 Aug 23
PMID 21856269
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Heterozygous germline mutations in PRKCSH cause autosomal dominant polycystic liver disease (PCLD), but it is not clear how they lead to cyst formation. We investigated whether mutations in cyst epithelial cells and corresponding loss of the PRKCSH gene product (hepatocystin) contributed to cyst development.

Methods: Liver cyst material was collected through laparoscopic cyst fenestration from 8 patients with PCLD who had a heterozygous germline mutation in PRKCSH. Tissue sections from 71 cysts (2-14 per patient) were obtained for hepatocystin staining and mutation analysis. Cyst epithelium was acquired using laser microdissection; DNA was isolated and analyzed for loss of heterozygosity (LOH) and somatic mutations using restriction analysis and sequencing. Common single nucleotide polymorphisms (SNPs) in a 70-kilobase region surrounding the germline mutation were used to determine variations in the genomic region with LOH.

Results: The wild-type allele of PRKCSH was lost (LOH) in 76% of cysts (54/71). Hepatocystin was not detected in cyst epithelia with LOH, whereas heterozygous cysts still expressed hepatocystin. The variation observed in the LOH region analysis indicates that cysts develop independently. We also detected somatic mutations in PRKCSH in 17% (2/12) of the cysts without LOH. Trans-heterozygous mutations in SEC63 were not observed.

Conclusions: Among patients with PCLD who have a heterozygous germline mutation in PRKCSH, we found secondary, somatic mutations (second hits) in more than 76% of the liver cyst epithelia. PCLD is recessive at the cellular level, and loss of functional PRKCSH is an important step in cystogenesis.

Citing Articles

Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease.

Boerrigter M, Duijzer R, Te Morsche R, Drenth J Genes (Basel). 2023; 14(9).

PMID: 37761895 PMC: 10530326. DOI: 10.3390/genes14091755.


A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease.

Waddell S, Yao Y, Olaizola P, Walker A, Jarman E, Gournopanos K Sci Transl Med. 2023; 15(713):eabq5930.

PMID: 37703354 PMC: 7615241. DOI: 10.1126/scitranslmed.abq5930.


Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum.

Boerrigter M, Te Morsche R, Venselaar H, Pastoors N, Geerts A, Hoorens A Genes (Basel). 2023; 14(8).

PMID: 37628703 PMC: 10454741. DOI: 10.3390/genes14081652.


Molecular Mechanisms of Isolated Polycystic Liver Diseases.

Yu Z, Shen X, Hu C, Zeng J, Wang A, Chen J Front Genet. 2022; 13:846877.

PMID: 35571028 PMC: 9104337. DOI: 10.3389/fgene.2022.846877.


Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.

Olaizola P, Rodrigues P, Caballero-Camino F, Izquierdo-Sanchez L, Aspichueta P, Bujanda L Nat Rev Gastroenterol Hepatol. 2022; 19(9):585-604.

PMID: 35562534 DOI: 10.1038/s41575-022-00617-7.